million even achieve in of an not unheard an This just million basis. drug the our very In we've past you clinical nature X.X years, efficiency and per the additional first-in-human to much. On of programs oncology and companies program. biotech programs, successfully of advancing cost developed initial and AI trials to thank insights something XX a David, $X metrics is X consistent are $X average, launched average larger a years to able discovery. agility, approach. These been have AI are these testament groundbreaking to from on
not indications, clinical multiple a Today, -- and make drugs, could about drugs. these getting we and unheard manufacturing validating AI really We're patented, we're them drugs just developing trials designing actually drugs have that's dosing pace how not cost of. patients. them launching conjecturing into them, at We're
model figures the of not an is So reminder and in and startling it's pace pharma changes the it's R&D the done, drug can drug approach not that big these the availability. or actually drug stark that traditional a to of sustainable. improve a that reminder pricing make as strategy, not need big serve It's right pharma to terms effective be
Starlight availability, instances the economic escalating adoption increasing to be cost Therapeutics, of standard a we believe at new companies. birth, and in prices new and approaches future our X be and industry data-driven creation oncology of set will continues and will drug with this it's pharma. discovery opportunities assets new to really fundamentally. development Starlight potential we elevate computational along and in innovative into that its of new could a transformative technologies and the at that cancer to needs development And drug political specific We approach drug issue drug can clear believe cancer drug approach development. entirely AI new over an company, clinical many drug rethink be its stage When pressures think at generate of value to the of and of the forefront The which long-term
us well and absolutely trials walking On June discussing CMO will fascinating. join our you'll as trials. and neuro-oncology of Please Mark the p.m. at XX, of And be find Chamberlin, and X:XX Mark development is plans Starlight, it upcoming a Dr. neurology-focused as highlights knowledge on and discussing and papers, absolutely June encyclopedia XX. future the STR-XX the
highlight STAR things the that XXX. me of about let excited some get So me
of about drug, First antitumor potent uniquely molecule of actually effect status. temzolamide, existing than that all, the a care it higher standard And about unlike temzolomide. the has is it X,XXXx care MGMT doesn't
MGMT, with know, nonresponsive increasingly. you As tumors the become
MGMT Some other nitrous positive chemotherapies some cancer. at attacking way forms as temzolimide a methylation like develop tumors or combat of are to ureas or MGMT onset the
some we did potency. lines? negative one the and didn't question, resistant work across sometimes GMT far, can we you temzolomide, see which GBM board to find MGMT far Can all I we on is right positive super high slide. seems we super especially cell very we the that you're with at was that to on superior of temzilomide can what probably MGMT lines our potency in believe respond both the that cases, in drug and find and the on the both in So did central potency, of temzolamide studies And cell responsive? looked at And positive
GBM. adult has single So no agent in approved therapy been
to including shown with pointed both, which, type, this help in again, there's trial, second orphan area which actually us the going wild on launching our malignant designation I critical an We after We've recurrent out earlier as in GM. effectiveness gliomas, the in need. and of to IDH we're will of XXXX. high an discussion, go drug have plan We half treat
also couple drug And would actually, this what could is other the why prodrug. a central how it's to There's a of they about armamentarium. -- think like positioned, reasons fixture it's a GBM, call talk I in it be we
an kind I XXX cancers. current to the of is accepted repair some well got so understood well, way nanomolar and breaks a it we've temzolimide CNS themselves which more some even ICXX GBMs. wonderful is average, -- minutes. that of some it nitrous elimination than like creates the it's in much double-stranded ureas seen ranges, works alkylation, bricks to of it very And create kind seen value at most mainstay sub-XXX the sometimes can't unlike through about breaks. double-stranded And approved is a unique position So DNA a in cancers, position. these as XX be which some period can sub-micromolar Adnasene far we've and XXX on of the of potent But nanomolar It potency, mentioned, the that
the very cancer the a that occurs mentioned, means this it's bioctivation, feature inside the the once prodrug unique cell. is because I biactivation -- intracellularly Now
mentioned, a do its we that those continues managed So outside to in alkylating increase toxicity. as nausea have be the potentially think the it I safety probably will vomiting can the from typical doses, alkylating our but But agents, ability in clinic. and to agent see we again, easily damage low, kind as the like data we pretty haven't But of cells trials. seen we'll dose-limiting is are come and other
about drug. PTGRX. elimination some features number mentioned, XX-minute a So also cancers. And well-known a be this has a the different are and CNS value intracellularly to period. strong like ICXX these shown of inside It's has active and I cell through wonderful a in mechanism bioactivation of of unique cancer It
from of in So humans. from data is models. this to in to critical And vitro was born vivo drug to we're now we this vivo advanced really lots moving in because points. And it moved naturally more
current safety enrolled the GBM trial, Ia patients. Phase have In we fact, in
understand Starlight that learn features we're and inform trials. And the and so see to response and GBM the on will them we safety watching guide GBM early dosing, can very about carefully later the also what
in promising drug RADAR high-growth Now conjugates entirely, into will -- another this a be been highly it's incorporated that of is obviously, area very a And antibody our -- we've working area area. we module.
the we've development module. to in a RADAR so needed for been has that module indications. actually of to clinically current code I'm also able sorry, identifying the our of indications radar And And our the RADAR us valuable allowed repurpose and advance clinically targets rescue valuable inside of platform, by -- the and lot
range that period we advance So cancer Consortium, that kill And moving picomolar the University to We of some quite months. more where we show for produced a ADCs. preclinical saw, announced a were the did the we Magic rate, ADC. the cryptofisin-ADC our about year than Bullet commonly that data pryptofysin tumors. solid this data excited used X we're in that able cell Bellefield the to work an in on with potency shared the earlier wide this XX% in much we we of because other that cryptos we was of which
got very so that us And excited.
was fact, cancers. HERX with case medium expression low it also and In the
existing cryptofisin, get with that good HERX really coming kind potent are HERX with expression about the doesn't So of in the existing of HERX outside colorectal even expressed cancers the trigger like molecules of of in even ADCs, ADC really of gastric, does XXx some to bispecifics expression the even the right out. of levels, response some seem market. than some in some level The bladder, there more the other we But ovarian. get breast,
is exciting preclinical data. this So
continue We're and these cancers. mentioned, go develop targets. But of several after I additional have low HERX expressing going medium to we to also, as many it,
not look unique targets after go of with we go them, well. we've only as with how actually modeled thousands through we at targets but through payloads really to So to we've and gone after criticism, want which other thousands and can
payloads hope building tumors We characterize payloads literally been potent will can we're in work select that against based because module and we that those want of certain predict But the the of so that tumors. also really overnight. mutation those of potent what those on And can unique to beginning and of we some importantly, understand our and availability super really microenvironment monetize the the up to but ADC more we've the synergy we can with and we tumors. and this antibodies mechanisms asset it those mutations on affect tumors see very
the this though smarter So very be expressed isn't ADCs -- we about different, to target but to similarly expression exciting. and do cheaper litany, so just the can library of very ADCs, be even think is it patterns you develop clinic importantly, faster, to can a the And Alta have goal to that to very, we pretty do targets this it doing faster. of bring all
so doable. the seen, very preclinical this think in work we've we And is
payloads. for development. with a important experimenting to biparatopic is fragment-based things structures, that be type And going structures. future this now a importantly, are actually experimenting are drug bispecific more We're very do. These other oncology area ago, with the all we We structures, year of couldn't
there's share of with stakeholders a details big a because these community, to and the want doing. We investors, the programs. of a lot we've educate an called in of the launched share our these share It's to with We Wednesdays. think what Webinar want insights general our focus part effort public to and we're lot oncology community, inform, more I our widely.
of efforts. had feedback. just our XXX. X We the LP great one And every very We focus Wednesday, month, will did on so a on we'll have first webinar which
groups also breadth inbound to as some groups what was it a spurred the actually focus Hope it groups promoted from on groups. EGFR socially activity groups fact, that smokers, from and never like In of various groups and result patient that
patients because important trials. lowers great attracting our of So this is these cost it to
and webinars of number who's of great experts been there. specifically. a pancreatic that with high a GU luminary had importantly, hosting areas in brilliant Papa kind a She's being, coming up, Copenhagen. webinar Hal pancreatic X cancer We've cancer University field in X number be a the and need. wonderful years. KOLs from of this both of Yver, We've He's Chase, and in bladder, collaborator just of also cancer Fox a Dr. followed the he'll up in most got in have for We of interactions pancreatic, global Dr. unmet human
cancer, drug in also cancers we've damage seems repair bladder tumors, our bladder that's a as seen to part DDR I have these very deficient to referred about earlier of and important where tumors. potency cancer tremendous what response. what's deficiency, XX% And have of super called In big -- because DNA bladder
So them. again, way give informed. to we Wednesdays updates. sharing major forward webinar And people to will a these It's stay really look
agnostic call, posters It's in works about a highly mutation drug some talk of potent as AACR publications the and I our exciting meeting earlier around Let's mentioned annual had our the we LPXXX. very damaging TPXX at no a today. active seen enrolled, DNA in poster well, a candidate And agent really we cohorts. dosed. now We're first not trial Phase X but We've beginning it's no again, dose-limiting toxicities. in lymphomas, in cohort. the the Ia/Ib seen we've be in It's lymphomas, and we're third clinical fully non-Hodgkin's issues to believe,
PR, of a that repair and scientists on repair our Georgetown Research again, lethal XXx are when the solid of very or over focuses have University that -- and LinkedIn range We opportunity X very mechanism DNA These I've and we've these some published what's think damage ratios research of -- in synergistic that highest XXX among against Cancer PARP is a sales, with the fact, drugs inhibitors exciting of up the activity publication diverse tumors for it deficient the on about communications. our And exciting causes double-stranded combination breaks our XXX annual this called or website. of on and many range HRD of a paper also in SAP publication very ATM trials also and DNA because scores available Lantern a drug the seen these our moving seen. sensitive it very, of a subset we very -- is combination billion BRCA $X now that our A and link And HRD drugs basically plus little is is homologous up to SHAP homologous and deficient for repair of deficiencies. to the sees HRD excited the up deficiencies, HR so in the more BRCA we're a deficient. opens make about in lots
by molecule theory mechanism a the inhibitors can is can PARP inpatients. have And is be for inhibiting PARP because the becomes PARP it we combining reintroduce complementary we of to amount unique dosage also works oftentimes this lower PARP a where with So that the unusable and very repair.
blocks itself, enzyme to tries DNA and So fix not it try available cells so repair when the the DNA and it's at it. to to can't to cancer
very and that's they brakes. complementary XXX, causing remember, LP-XXX lethal very by these Now work because
So the -- and doubles the trended and will inhibit introduces even repair of sign. a dose XXX brakes. Park lower
And element a a so more tumors. sensitive X we available. create to X DNA And in more longer, have think that's X in of and about response to these of big perhaps we durable repair can some X tumors range tumors, damage
launched other So where XXXX strengthened that's has a We our great drugs year influencing emerged XXXX future journeys impacting in and development the patients It's companies. to decisions the for year for trials. a really us for where pivotal of of insights. progress. That's cancer trials, our our insights a big their progress market fight is also we as future are now XXX. cancer.
only continue effective viable stage toward a of our creating I exciting company, an affordable, collective of set for fostered and the more innovation, industry. future transformation can patients, economically but Our to actually but solutions the for today, transformational importantly, for the pace accelerate. lives We're not of the faster. will think, a time that only And improve cancer not it's efforts trajectory where in dedication have we in and shift
I'd open or any like to clarifications. that, to with So questions call the now
If ways. X do of a you a can in Instructions] you'd question, I'll break X like take so some to ask for [Operator So questions.
